You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Recent developments in mass-spectrometry-based targeted proteomics of clinical cancer biomarkers
|
|---|---|
| Published in |
Clinical Proteomics, January 2024
|
| DOI | 10.1186/s12014-024-09452-1 |
| Pubmed ID | |
| Authors |
Deborah Wenk, Charlotte Zuo, Thomas Kislinger, Lusia Sepiashvili |
| Abstract |
Routine measurement of cancer biomarkers is performed for early detection, risk classification, and treatment monitoring, among other applications, and has substantially contributed to better clinical outcomes for patients. However, there remains an unmet need for clinically validated assays of cancer protein biomarkers. Protein tumor markers are of particular interest since proteins carry out the majority of biological processes and thus dynamically reflect changes in cancer pathophysiology. Mass spectrometry-based targeted proteomics is a powerful tool for absolute peptide and protein quantification in biological matrices with numerous advantages that make it attractive for clinical applications in oncology. The use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) based methodologies has allowed laboratories to overcome challenges associated with immunoassays that are more widely used for tumor marker measurements. Yet, clinical implementation of targeted proteomics methodologies has so far been limited to a few cancer markers. This is due to numerous challenges associated with paucity of robust validation studies of new biomarkers and the labor-intensive and operationally complex nature of LC-MS/MS workflows. The purpose of this review is to provide an overview of targeted proteomics applications in cancer, workflows used in targeted proteomics, and requirements for clinical validation and implementation of targeted proteomics assays. We will also discuss advantages and challenges of targeted MS-based proteomics assays for clinical cancer biomarker analysis and highlight some recent developments that will positively contribute to the implementation of this technique into clinical laboratories. |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 18% |
| United States | 1 | 9% |
| Unknown | 8 | 73% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 55% |
| Scientists | 4 | 36% |
| Science communicators (journalists, bloggers, editors) | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 6 | 21% |
| Researcher | 4 | 14% |
| Student > Ph. D. Student | 2 | 7% |
| Student > Master | 1 | 4% |
| Student > Doctoral Student | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 12 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 6 | 21% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Chemistry | 2 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Arts and Humanities | 1 | 4% |
| Other | 4 | 14% |
| Unknown | 12 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 March 2024.
All research outputs
#5,333,080
of 25,457,858 outputs
Outputs from Clinical Proteomics
#62
of 334 outputs
Outputs of similar age
#63,368
of 289,040 outputs
Outputs of similar age from Clinical Proteomics
#2
of 10 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 334 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,040 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.